Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Curent Deferred Tax Liability (2016 - 2019)

Assembly Biosciences (ASMB) has 5 years of Curent Deferred Tax Liability data on record, last reported at $3.3 million in Q1 2019.

  • For Q1 2019, Curent Deferred Tax Liability rose 52.26% year-over-year to $3.3 million; the TTM value through Mar 2019 reached $3.3 million, up 52.26%, while the annual FY2018 figure was $3.3 million, 52.25% up from the prior year.
  • Curent Deferred Tax Liability reached $3.3 million in Q1 2019 per ASMB's latest filing, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Curent Deferred Tax Liability topped out at $11.6 million in Q1 2015 and bottomed at $2.1 million in Q3 2018.
  • Average Curent Deferred Tax Liability over 5 years is $8.3 million, with a median of $11.1 million recorded in 2017.
  • Peak YoY movement for Curent Deferred Tax Liability: tumbled 81.13% in 2018, then soared 52.26% in 2019.
  • A 5-year view of Curent Deferred Tax Liability shows it stood at $11.6 million in 2015, then dropped by 4.14% to $11.1 million in 2016, then plummeted by 80.79% to $2.1 million in 2017, then soared by 52.25% to $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019.
  • Per Business Quant database, its latest 3 readings for Curent Deferred Tax Liability were $3.3 million in Q1 2019, $3.3 million in Q4 2018, and $2.1 million in Q3 2018.